FierceBiotech Apr 1, 2026 KBP hopes to revive troubled heart drug at center of deal fraud dispute with Novo Nordisk
FierceBiotech Mar 31, 2026 Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
FierceBiotech Mar 31, 2026 Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play
FierceBiotech Mar 31, 2026 Obesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic
FierceBiotech Mar 31, 2026 AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan
FierceBiotech Mar 31, 2026 Lipella files for bankruptcy, ending dream of developing mouth inflammation drug
FierceBiotech Mar 30, 2026 Astellas axes early Sjögren’s trial in latest setback for autoimmune disease community
FierceBiotech Mar 30, 2026 Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies
FierceBiotech Mar 30, 2026 Viridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincing
FierceBiotech Mar 30, 2026 Boston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial
FierceBiotech Mar 30, 2026 Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals
FierceBiotech Mar 30, 2026 Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025